Mountain Crest Acquisition Corp. V

Mountain Crest Acquisition Corp. V Annual Report - A Critical Investor Brief

Mountain Crest Acquisition Corp. V (MCAG), a Special Purpose Acquisition Company (SPAC), faces a critical juncture. This summary distills key financial, operational, and strategic insights from its recent 10-K filing, offering investors a clear view of its performance, significant challenges, and urgent path forward.

1. Business Overview

Mountain Crest Acquisition Corp. V (MCAG) launched in April 2021 as a "blank check company." Its sole purpose: to merge with a private operating business and take it public. MCAG focuses its search on North America and the Asia Pacific regions, specifically excluding China, Hong Kong, and Macau. As a SPAC, MCAG's primary goal is to identify and complete a business combination within a set timeframe. However, the past year proved challenging; MCAG did not achieve its primary objective of merging with a target. Its core mission remains unfulfilled as the company continues its search.

2. Financial Performance

As a SPAC, MCAG does not generate traditional revenue or profit from operations. Instead, we assess its financial performance by how it manages its trust account, its operating expenses, and its overall liquidity.

• Trust Account & Redemptions: On December 31, 2022, MCAG held approximately $150.0 million in its trust account, representing proceeds from its initial public offering (IPO) and subsequent investments. A significant event occurred when shareholders approved an extension to the merger deadline: shareholders redeemed 1,405,134 shares, withdrawing approximately $14.3 million from the trust account (based on an estimated redemption price of $10.20 per share). This reduced the capital available for a future business combination to approximately $135.7 million as of the extension date. This reduction directly impacts the size and attractiveness of potential merger targets.
• Operating Expenses: For the fiscal year ended December 31, 2023, MCAG incurred total operating expenses of approximately $1.5 million. These costs primarily covered legal, accounting, and administrative fees related to its search for a target and compliance.

3. Management's Discussion and Analysis (MD&A) Highlights

Management's discussion reveals the significant developments and challenges that have shaped the company's financial condition and operations. The past year brought substantial hurdles, highlighting the inherent risks of SPAC investing.

• Failed Business Combination: The most critical event was the termination of the Business Combination Agreement with AUM Biosciences Pte. Ltd., a clinical-stage oncology company. After multiple amendments and extensive efforts, AUM Biosciences terminated the agreement on June 8, 2023. This forced MCAG to cancel its shareholder meeting and restart its search for a new target, marking a substantial setback for its core mission.
• Nasdaq Listing Compliance Issues: MCAG received multiple warnings from Nasdaq, jeopardizing its listing status:
  • Market Value of Listed Securities (MVLS): In April 2023, Nasdaq notified MCAG that its MVLS had fallen below the $50 million minimum requirement for 30 consecutive business days. The company faced an October 2, 2023, deadline to regain compliance.
  • Publicly Held Shares: In May 2023, the company received another notice for failing to maintain at least 1.1 million publicly held shares.
  • These non-compliance issues put MCAG at risk of delisting, which would severely impair the liquidity and marketability of its shares. This could make MCAG less attractive to investors and potential merger partners. The company applied to transfer its listing to The Nasdaq Capital Market, which may have different requirements, but the outcome remains uncertain.
• Merger Deadline Extension: To avoid liquidation, shareholders approved an amendment to the company's charter in May 2023. This extended the deadline to complete a business combination from May 16, 2023, to February 16, 2024. While necessary, this extension came at the cost of significant shareholder redemptions and potentially further sponsor contributions.

4. Risk Factors

Investing in MCAG carries substantial risks, particularly given its current status and the nature of SPACs.

• Failure to Complete a Business Combination: This is the paramount risk. If MCAG fails to identify and successfully merge with a target company by the February 16, 2024 deadline, it will be forced to liquidate. In this scenario, shareholders would receive only their pro-rata portion of the remaining trust account, estimated at approximately $10.20 per share (as of the last redemption date). This amount could be less than their initial investment or the current market price.
• Delisting from Nasdaq: Ongoing non-compliance with Nasdaq's listing rules poses a severe threat. Delisting would significantly reduce trading liquidity, making it harder for investors to buy or sell shares, and could further depress the stock price.
• Further Share Redemptions: Any future extension requests or perceived lack of progress could trigger additional shareholder redemptions, further depleting the trust account and reducing the capital available for a merger.
• Competition and Target Quality: The SPAC market remains highly competitive. MCAG's failed deal and listing issues could make it less attractive to high-quality private companies seeking to go public.
• Dilution: Potential future dilution from the exercise of warrants, founder shares, or any private investment in public equity (PIPE) associated with a business combination remains a risk.
• Sponsor Incentives and Conflicts of Interest: While the sponsor is incentivized to complete a deal, their economic interests (e.g., founder shares) may not always perfectly align with those of public shareholders, especially regarding a target's valuation.

5. Financial Health

The company's financial health hinges on its trust account balance, its ability to cover operating expenses, and its overall liquidity.

• Trust Account: As discussed in the Financial Performance section, the trust account, after significant redemptions, held approximately $135.7 million. This balance represents the primary asset intended for a business combination.
• Debt: The company reported an unsecured promissory note of approximately $108,000 issued to its former accounting firm, UHY Advisors/UHY LLP, accruing interest at 8% per annum. This indicates MCAG's reliance on debt for operational funding.
• Cash & Liquidity: As of the reporting date, MCAG held approximately $200,000 in cash outside the trust account to cover its ongoing operational expenses. The company's ability to fund operations largely depends on loans from its sponsor or affiliates, which may or may not be repaid. This reliance on sponsor loans for working capital highlights a constrained liquidity position outside of the protected trust account.

6. Competitive Position

The SPAC market is crowded and highly competitive. MCAG's competitive position has likely weakened due to its failed merger attempt with AUM Biosciences and its ongoing Nasdaq listing challenges. Reputable private companies often prefer to merge with SPACs that demonstrate a strong track record, robust capital, and stable public listing status. The significant redemptions also reduce MCAG's financial firepower compared to other SPACs, potentially limiting the size and quality of target companies it can pursue.

7. Future Outlook and Strategy

The immediate future for Mountain Crest Acquisition Corp. V is binary: secure and complete a business combination by February 16, 2024, or liquidate. Simultaneously, resolving the Nasdaq listing issues is critical to maintaining its public market presence.

MCAG has announced no changes to its leadership team or fundamental strategy. The company remains committed to its original objective of identifying and completing a business combination. However, immense pressure rests on the current leadership to execute this strategy successfully before the looming deadline. The broader SPAC market continues to face headwinds, including increased regulatory scrutiny, higher redemption rates, and a more challenging environment for identifying and valuing suitable merger targets. These market trends, combined with MCAG's specific challenges, create a high-stakes environment as the company races against its deadline.